- An omega-3 drug reduces ischemic events among patients taking statins and who have well-controlled low-density lipoprotein cholesterol and existing cardiovascular (CV) risk factors.
- Treating 1000 patients could prevent 159 events each year.
- Results are from planned analysis of Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) of icosapent ethyl (IE; Vascepa), a derivative of the omega-3 fatty acid eicosapentaenoic acid.
Why this matters
- This drug is already used to lower high triglycerides.
- REDUCE-IT data for 8179 patients taking IE 4 g/day or placebo followed for a median 4.9 years.
- Primary composite endpoint: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina.
- Secondary composite endpoint: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
- Funding: Amarin Pharma, which markets Vascepa.
- Overall, IE was associated with fewer primary endpoint events vs placebo:
- 61 vs 89 per 1000 patient years;
- Rate ratio, 0.70 (95% CI, 0.62-0.78; P<.0001>
- Similar reductions for secondary endpoint events.
- Exploratory (but prespecified) analysis, used 1 post hoc method of several applied.